BTG Share Discussion Threads

[cumnor] 15/4/2012 22:22

Shire too big for them. BTG next, maybe even for SHP given it's wide portfolio?

[bargainbob] 15/4/2012 20:20

So Astra will not be taking over Shire.LOL

IMHO Astra will be going for smaller companies. Think there more chance BTG will be a target than Shire.

Time will tell.

[cockneytrader] 15/4/2012 17:52

article in sunday times about astra zeneca with reference to possible takeovers, shire are mentioned.

[enormouswillie] 15/4/2012 12:22

What would they need to get in the FTSE-100 ? A share price of about 10 quid which would equate to a market cap of around 3 billion I guess. Can't see Louise letting up before she achieves her ambition of becoming one of the UK's top 100 listed companies. She is paving a golden path to that pot of gold and no one is gonna spoil her rainbow.

[bargainbob] 15/4/2012 08:54

Still recall the Elevator to the FTSE and a £40 target. Over adecade ago from the chronics

[moretimeforlife] 15/4/2012 08:17

BB, maybe in the past........but the new improved BTG has more than one antidote to recover quickly even from a bite by Le Chronic Investor :)

[semper vigilans] 13/4/2012 12:28

Investors Chronicle have rated BGC a buy - should we be worried?

[archie meads] 13/4/2012 12:19

In a similar...vein:

[moretimeforlife] 13/4/2012 12:08

"On the mountains of truth you can never climb in vain: either you will reach a point higher up today, or you will be training your powers so that you will be able to climb higher tomorrow." Nietzsche

[bargainbob] 12/4/2012 22:18

Tomorrow could be break out.

[bargainbob] 12/4/2012 22:17

Tomorrow could be break out.

[superbarnet] 12/4/2012 15:54

Looks like we are on the road to £4.

[moretimeforlife] 10/4/2012 11:51

The combination of

- progressive profitability and revenue growth expectation
- positive newsflow
-likely inflow of ISA invesments for the new tax year
- recognition by astute investors that the management team seems to have adopted an "under promise and over deliver" approach in recent times

could power the rise to higher highs ahead of the results on 21st May and continue the momentum to deliver significant value over next 21 months.

Even happier days ahead!

Good luck to fellow investors.

NAI/DYOR etc

[gregsc] 10/4/2012 10:28

This from the IC a few days ago, just in case some of you haven't already seen it.


A trading update from BTG this month helped confirm the group's place as possibly the most successful UK pharmaceutical play outside of the big three. Indeed, the robustness of BTG's mix of royalty streams has led management to upgrade revenue expectations – sales guidance for the year to the end of March 2012 has now been substantially raised, from £160m-£165m to £190m-£195m.

That largely reflects better than expected royalties from its BenefiX haemophilia drug, which benefited from rapid de-stocking prior to the drug going off-patent. Alongside this was a strong performance from prostate cancer drug Zytiga, which will soon launch in the US. In addition, the upgraded sales forecasts include about £10m in one-off milestone payments.

BTG's development partners have also enjoyed a run of positive regulatory decisions this year – which has helped build momentum. As well as Zytiga, renal treatment Voraxaze was approved in January and will be rolled out in the US market by the end of this month. Meanwhile, Sanofi-Aventis expects to file Lemtrada (Campath) as a treatment for multiple sclerosis with US and EU regulators by the second quarter. First results are also expected from the self-funded Phase III trials for its Varisolve varicose veins product. BTG will announce full-year results on 21 May.

Peel Hunt says...

Hold. Significant upgrades in expected revenues for full-year 2012 has led us to improve our cash profit estimate from £32m to £52m – leading to a year-end net cash position in excess of £100m, with adjusted EPS anticipated to be 9.1p. However, we remain cautious about the outlook for 2012. For example, anticipated success for the next two Varisolve trials is largely in the price while, with AstraZeneca's Phase II trial for CytoFab, we think there's a strong chance the drug will fail to extend survival. The shares are now rated on an enterprise value to sales multiple of five times and we continue to think the risk/reward profile is fairly balanced.

Jefferies Securities says...

Buy. Newsflow momentum, in addition to impressive growth, is likely to drive significant outperformance. The group is now entering a period of considerable growth and sustained profitability and we believe that – when valuing the shares – it is unrepresentative to apply near-term multiples. Accordingly, we now value BTG by applying a discounted enterprise value to cash profits multiple for full-year 2019 – by which time the group should be in a more stable growth phase – and a PE multiple based on historic biopharma multiples. That yields a 410p price target and we retain our buy recommendation.

[superbarnet] 06/4/2012 18:26

I am back in now that the market seems to have settled down. I have followed this since the protherics days and the chart says it all. This company will be in ftse 100 at some stage and the superb product range will help the share price hit new highs.

[cumnor] 05/4/2012 09:07

Bitty trades as we have at present reflect the needs of small PIs and st traders. I expect IIs to start increasingly get interested here as secure growth play in a safe pharma sector but with massive potential. They will buy to hold for pension funds etc as safe choices are limited and the share price will start to reflect the company's potential, hopefully in the new tax year.

[moretimeforlife] 05/4/2012 09:07

Agree ade, After the dynamic ups and downs since 2005 it deserves to keep rising and deliver significant value for all of us long term holders over the next 21 months.

....and this time even GB hasn't returned to give his contrarian views :)

Dum spiro spero

[adejuk] 05/4/2012 09:02

indeed mf
this is the next au. imo
cant see us surviving beyond 2013

[moretimeforlife] 05/4/2012 08:55

ade, finishing up today would be good as that would position it well for the new tax year ISA effect next week which should be the start of the next wave to higher highs for 2012.....enjoying the ride...good luck.

NAI/DYOR etc

[adejuk] 05/4/2012 08:29

i think today could see the beginning of the response after such a good day yesterday in the face of a global sell-off

[moretimeforlife] 05/4/2012 07:55

Deutsche Bank Buy Recommendation - Target Price Raised to 400p

JP Morgan Cazenove Overweight Recommendation - Target Price 415p

+

"Tempus in The Times mulls pharma firm BTG, which appears to have broken free from the cash burning cycle of simply developing medicines by instead focusing on the treatments it already owns and marketing them hard.

Its main drugs are BeneFIX for haemophilia (which has come off patent) , CroFAB for snakebites and DigiFab, which helps patients recover from heart failure. But there have been promising results from other compounds, often bought by acquisitions.

Tempus notes BTG doesn't have a decent price to earnings ratio, but thinks it's doing better than almost all its sector peers and may be a buy for the long term."

[cumnor] 04/4/2012 19:54

Something to aspire to. A rare bio/pharma that has survived and will flourish. £17 easily achievable if varisolve takes off and a couple of the beads succeed in oncology Tx. Mrkt cap of small pharma (by US and Major standards) achievable, given it's pipeline. imo

[greenpastures2] 04/4/2012 19:20

Just shows how silly so many of us were back in 2000. I remember Autonomy selling for £30 a share in 2000 and when Hewlett Packard bought it for £25 a share last year a common reaction was they had paid a full price for it.

[buywell2] 04/4/2012 18:08

Respect to Mr buffet2 since he started this thread when the share was around 210p

The chart still looks like this long term ,